A Phase 3 interventional study of Tirzepatide and Placebo in Type 1 Diabetes, Obesity and Overweight, sponsored by Eli Lilly and Company. Active, not recruiting at 79 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Eli Lilly and Company.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 9th largest by planned enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 in phase 3, and was the 72nd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18–70
Eli Lilly and Company · Sites in United States, Australia, Belgium and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in United States, Australia, Belgium and 16 more countries
Ages 1–35
Eli Lilly and Company · Sites in Germany
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 8 · Phase 3 25 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 465 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 62 across the 72 interventional studies, 28 across the 3 observational. Of the 66 that completed or were terminated, 49 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
4 of the studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07803744Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | 2026-12 |
| NCT06945406Eli Lilly and CompanyA Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tirzepatide subcutaneously (SC)
Drug: Tirzepatide
Participants will receive placebo SC
Drug: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 40
Change from Baseline in HbA1c
Time frame: Baseline, Week 72
Percentage of Time Continuous Glucose Monitor (CGM) Glucose Values are Between 70 and 180 milligrams per deciliter (mg/dL) (3.9 and 10.0 millimoles per liter (mmol/L)) Inclusive, Per Day
Time frame: Within 30 days prior to Week 40, Within 30 days prior to Week 72
Change from Baseline in Body Weight
Time frame: Baseline, Week 40, Week 72
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 40, Week 72
Percentage of Participants with ≥5% Body Weight Reduction
Time frame: Baseline, Week 40, Week 72
Percentage of Participants with ≥10% Body Weight Reduction
Time frame: Baseline, Week 40, Week 72
Percentage of Participants with ≥15% Body Weight Reduction
Time frame: Baseline, Week 40, Week 72
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 40, Week 72
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 40, Week 72
Percent Change from Baseline in Fasting Triglycerides
Time frame: Baseline, Week 40, Week 72
Percent Change from Baseline in Fasting Non-High-Density Lipoprotein (non-HDL) Cholesterol
Time frame: Baseline, Week 40, Week 72
Percent Change from Baseline in Total Daily Insulin Dose
Time frame: Baseline, Week 40, Week 72
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, Week 40, Week 72
Change from Baseline in EQ-5D-5L
Time frame: Baseline, Week 40, Week 72
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 18 months is close to that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide